NCT06975462View on ClinicalTrials.gov

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions
Breast Cancer Metastatic
Interventions
COMBINATION_PRODUCT

SHR-A1811 and radiotherapy

SHR-A1811:4.8mg/kg radiotherapy: 800cGY\*5

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER